Drugs / ATLG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06525519 | Jul 2024 → Jul 2025 overdue | disease related to hematopoietic stem cell transplant | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATLG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525519 ↗ |
| Modality | Protein / enzyme biologic | “anti-T lymphocyte globulin (ATLG)-based protocols have been widely used worldwide for GVHD prophylaxis.” NCT06525519 ↗ |
| Route | Intravenous | “5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation).” NCT06525519 ↗ |